Partners - Ardelyx

We have agreements for the development and commercialization of tenapanor outside of the U.S.

In November 2017, we executed a license agreement with Kyowa Kirin Co. Ltd., for the development and commercialization of tenapanor for cardiorenal diseases and conditions associated with them, including hyperphosphatemia, in Japan. Tenapanor, branded as PHOZEVEL^®, is currently available for the improvement of hyperphosphatemia in adult patients with chronic kidney disease (CKD) on dialysis in Japan.
In December 2017, we executed a license agreement with Shanghai Fosun Pharmaceutical Industrial Development Company Limited for the development and commercialization of tenapanor for irritable bowel syndrome with constipation (IBS-C) and hyperphosphatemia related to chronic kidney disease in China.
In March 2018, we executed a license agreement with Knight Therapeutics, Inc. to commercialize tenapanor in Canada for the treatment of IBS-C and hyperphosphatemia. IBSRELA^® (tenapanor) is currently available for the treatment of IBS-C in Canada.